• ADVAIR DISKUS is contraindicated for primary treatment of status asthmaticus or other acute episodes of asthma or chronic obstructive pulmonary disease (COPD) where intensive measures are required.
• ADVAIR DISKUS is contraindicated in patients with severe hypersensitivity to milk proteins

...continue reading

For patients aged 12 years and older, whose asthma is not well-controlled on a long-term control medication, such as an inhaled corticosteroid (ICS),

Consider ADVAIR DISKUS to help your patients achieve control

Results shown are from a 12-week, multicenter, randomized, double-blind, parallel-group study of 349 patients aged 12 years and older, with asthma (mean baseline FEV1 66% to 69% predicted) previously treated with medium doses of inhaled corticosteroids. Patients were randomized to treatment with ADVAIR DISKUS 250/50, fluticasone propionate 250 mcg, salmeterol 50 mcg, or placebo, each given twice daily through the DISKUS device. Patients were withdrawn from the study because of worsening asthma if they met any of the following criteria: a clinical exacerbation requiring emergency treatment, hospitalization, or use of asthma medication not allowed by the study protocol; a decrease in FEV1 of more than 20% from the predose FEV1 at the randomization visit; more than a 20% decrease from the mean morning baseline PEF (peak expiratory flow) on more than 3 of 7 days immediately preceding a visit; 12 or more albuterol puffs per day on more than 2 of 7 days immediately preceding a visit; or more than 2 nights with awakenings caused by asthma symptoms that required albuterol during the 7 days immediately preceding a clinic visit.1

Use of long-acting beta2-agonists for the treatment of asthma without concomitant use of a long-term asthma control medication, such as an ICS, is contraindicated.

FEV1=forced expiratory volume in 1 second.


  • ADVAIR DISKUS is indicated for the twice-daily treatment of asthma in patients aged 4 years and older. ADVAIR DISKUS should be used for patients not adequately controlled on a long-term asthma control medication such as an ICS or whose disease warrants initiation of treatment with an ICS/LABA (inhaled corticosteroid/long-acting beta2-adrenergic agonist).
  • ADVAIR DISKUS is NOT indicated for the relief of acute bronchospasm.

830417R0 March 2018